<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/16/zosano-pharmas-zsan-buy-rating-reaffirmed-at-maxim-group.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-16T08:21:32+00:00"/>
    <meta property="og:title" content="Zosano Pharma’s (ZSAN) Buy Rating Reaffirmed at Maxim Group"/>
    <meta property="og:description" content="Zosano Pharma (NASDAQ:ZSAN)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research note issued on Friday, AnalystRatings.com reports. They presently have a $8.00 price objective on the biotechnology company’s stock. Maxim Group’s target price would suggest a potential upside of 318.85% from the stock’s previous close. Several other […]"/>
  </head>
  <body>
    <article>
      <h1>Zosano Pharma’s (ZSAN) Buy Rating Reaffirmed at Maxim Group</h1>
      <address><time datetime="2019-11-16T08:21:32+00:00">16 Nov 2019, 08:21</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/zosano-pharma-corp-logo.png"/>
      </figure>
      <p>Zosano Pharma (NASDAQ:ZSAN)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research note issued on Friday, <a href="https://www.analystratings.com/articles/maxim-group-reaffirms-their-buy-rating-on-zosano-pharma-zsan//">AnalystRatings.com</a> reports. They presently have a $8.00 price objective on the biotechnology company’s stock. Maxim Group’s target price would suggest a potential upside of 318.85% from the stock’s previous close.</p>
      <p>Several other equities analysts also recently weighed in on the company. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ZSAN">ValuEngine</a> raised Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. BTIG Research dropped their price target on Zosano Pharma to $16.00 and set an “in-line” rating for the company in a research report on Friday. Cantor Fitzgerald dropped their price target on Zosano Pharma from $12.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.25.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ZSAN/price-target/">Zosano Pharma stock</a> opened at $1.91 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.22 and a current ratio of 1.22. The stock has a fifty day moving average of $1.91 and a two-hundred day moving average of $2.60. The company has a market capitalization of $35.98 million, a price-to-earnings ratio of -0.51 and a beta of 2.67. Zosano Pharma has a fifty-two week low of $1.41 and a fifty-two week high of $6.65.</p>
      <p>Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.03. On average, analysts forecast that Zosano Pharma will post -2.48 EPS for the current fiscal year.</p>
      <p>Large investors have recently made changes to their positions in the company. Aisling Capital Management LP grew its position in shares of Zosano Pharma by 900.0% in the second quarter. Aisling Capital Management LP now owns 16,000,000 shares of the biotechnology company’s stock valued at $5,232,000 after purchasing an additional 14,400,000 shares during the period. Vanguard Group Inc. grew its position in shares of Zosano Pharma by 118.6% in the second quarter. Vanguard Group Inc. now owns 957,025 shares of the biotechnology company’s stock valued at $3,129,000 after purchasing an additional 519,305 shares during the period. Jane Street Group LLC purchased a new stake in shares of Zosano Pharma in the second quarter valued at $36,000. BlackRock Inc. grew its position in shares of Zosano Pharma by 17.7% in the second quarter. BlackRock Inc. now owns 366,876 shares of the biotechnology company’s stock valued at $1,200,000 after purchasing an additional 55,105 shares during the period. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Zosano Pharma in the third quarter valued at $234,000. 34.09% of the stock is owned by institutional investors and hedge funds.</p>
      <p>
        <b>About Zosano Pharma</b>
      </p>
      <p>Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/understanding-options-trading/">Understanding Options Trading</a></p>
    </article>
  </body>
</html>